CJC-1295 Ipamorelin Dosage: What the Research Reports

Is there an official CJC-1295 ipamorelin dosage?

No. The two peptides are studied separately, and no published human trial tested them together as a fixed combination.

CJC-1295 and ipamorelin are often discussed as a pair because they act on the growth-hormone axis through different receptors, but that pairing comes from research interest and lab practice, not from a single approved protocol. Neither peptide is an approved drug for this use, and there is no regulator-set dose for the combination. The strongest honest statement is this: we can report the doses each compound used in its own study, and nothing more. Anyone presenting a precise "stack dose" as settled science is going past what the published record supports. For the full background on how the pair works and what each one is, see the CJC-1295 and ipamorelin complete guide.

What dosing does CJC-1295 ipamorelin research report?

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.

Two different kinds of data sit behind this question, and mixing them up is the most common error online. CJC-1295 has a human dose-escalation study that reported doses in micrograms per kilogram of body weight (mcg/kg). Ipamorelin's core pharmacology paper reported potency in animals as ED50 values, the dose that produced half of the maximum growth-hormone response, expressed in nanomoles per kilogram (nmol/kg). An animal ED50 is a pharmacology measurement, not a recommended human dose, and the two units are not interchangeable. The table shows exactly what each study used, with the source for each row.

A few things the table makes plain. The CJC-1295 doses are per kilogram of body weight, so a fixed "one size" microgram number does not match how the study was run. The ipamorelin numbers are animal ED50 values in nmol/kg, which is a potency measurement, not a human dosing instruction, and the study itself did not set a human dose. Presenting either figure as "the dose to take" reads more into the data than the authors reported.

How do you convert a research dose into syringe units?

Micrograms and nanomoles only become a syringe reading after a peptide is dissolved in a known volume of liquid, so the conversion is a labeling exercise, not a dosing rule.

Shown generically as a reference and not as an instruction to the reader: a U-100 insulin syringe reads 100 units per 1 mL. If any peptide is dissolved so that 1 mL of the final liquid contains 2500 mcg (for example, 5 mg dissolved in 2 mL), then 1 mcg corresponds to 0.04 units on that syringe. To go the other way, 1 unit on that same fill would draw 25 mcg. Change the amount of liquid and every number changes with it, which is why a "unit" figure means nothing without the concentration behind it. This arithmetic helps you read a label. It is not guidance on what to draw. For the mechanics of dissolving a lyophilized peptide, see the reconstitution guide.

Converting nanomoles is a separate step that needs the peptide's molar mass, and because ipamorelin's published figures are animal ED50 values rather than a human dose, there is no meaningful reader-facing conversion to make from them. Reporting the ED50 is fair. Turning it into a personal dose is not.

How often was each peptide studied, and why does half-life matter?

Dosing frequency in research follows half-life: CJC-1295 with DAC was built to last for days, while ipamorelin clears within minutes to hours.

CJC-1295 with DAC (drug affinity complex) binds to albumin in the blood, which is what stretches its action out. In the Teichman study, a single subcutaneous dose kept mean GH raised for 6 or more days and IGF-1 raised for about 9 to 11 days (Teichman et al., JCEM 2006, PMID 16352683). That long tail is why research on the DAC form used infrequent dosing rather than daily shots. Ipamorelin is the opposite: it is a short-acting pentapeptide that produces a brief pulse of growth-hormone release, closer to how the body's own signals fire, and it is cleared quickly (Raun et al., Eur J Endocrinol 1998, PMID 9849822). The two half-lives are a large part of why the peptides are studied together at all: one provides a sustained background signal, the other a sharp pulse. For a fuller pharmacokinetic breakdown, see the CJC-1295 ipamorelin half-life page, and for the head-to-head mechanism view, see CJC-1295 vs ipamorelin.

What are realistic expectations from these research-reported doses?

The studies measured hormone changes, mainly GH and IGF-1, not body-composition outcomes in healthy people, so the honest read is limited to what was actually recorded.

Teichman et al. reported changes in blood GH and IGF-1 after CJC-1295, and that is what the data support: a hormone response, measured over days (JCEM 2006, PMID 16352683). IGF-1 is worth understanding here because it is the more stable readout: the National Library of Medicine notes that IGF-1 manages the effects of growth hormone in the body and that, since GH swings through the day while IGF-1 holds steadier, measuring IGF-1 is a reliable way to track GH (MedlinePlus, National Library of Medicine, https://medlineplus.gov/lab-tests/igf-1-insulin-like-growth-factor-1-test/). Raun et al. reported that ipamorelin releases GH selectively in animals, with no significant rise in ACTH or cortisol beyond what GHRH itself caused, which is the finding that earned it the label "first selective growth hormone secretagogue" (Eur J Endocrinol 1998, PMID 9849822). What these papers do not establish is a promised result for a reader: fat loss, muscle gain, or an anti-aging effect on a timeline. Those claims go beyond the endpoints the trials measured. Treat the hormone data as what it is, a signal that the axis responded, and treat everything downstream of it as unproven in this context. Ipamorelin is also studied on its own; see the ipamorelin dosage page for that single-compound view, and the growth-hormone peptide research hub for how this class is studied against lean-mass questions.

What does research report on side effects at these doses?

CJC-1295 was described as safe and relatively well tolerated in its dose-escalation study, especially at the lower doses, but human safety data for the pair are thin and neither peptide is an approved medicine.

In the Teichman study, subcutaneous CJC-1295 was reported as safe and relatively well tolerated, and the authors noted this particularly at the 30 and 60 mcg/kg doses (JCEM 2006, PMID 16352683). Growth-hormone secretagogues as a class can cause transient injection-site reactions, flushing, or water retention, and raising IGF-1 is not risk-free, which is why medical supervision is the norm in any clinical setting. Ipamorelin's stand-out reported feature is selectivity, meaning it raised GH without significantly raising cortisol or prolactin in the animal work (Raun et al., Eur J Endocrinol 1998, PMID 9849822). None of this amounts to a safety guarantee for a person, and long-term human data on the combination are not established. On the regulatory side, CJC-1295 is not an approved drug and does not appear on the FDA's 503A bulk drug substances list for compounding, so it sits outside approved medicine (FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act). For the tolerability picture in depth, the complete guide and what peptides are give the fuller context.